https://stanfordhealthcare.org/publications/501/501449.html
501449 | Stanford Health Care
Phase I/II study of tipifarnib (ZARNESTRA (TM), farnesyltransferase inhibitor [FTI] R115777) in patients with myeloproliferative disorders (MPDs): Interim res
stanfordhealthcare